MLNM misses Phase II Crohn's endpoint

Millennium (MLNM) said in a placebo-controlled Phase II trial in 185 mild-to-moderate Crohn's disease patients MLN02 did not meet the primary endpoint of a decrease of >70 points on the Crohn's Diseas...